Background: Despite an increase in the familiarity of the medical community with 
the epidemiological and clinical characteristics of coronavirus disease 2019 
(COVID-19), there is presently a lack of rapid and effective risk stratification 
indicators to predict the poor clinical outcomes of COVID-19 especially in 
severe patients. Methods: In this retrospective single-center study, we included 
117 cases confirmed with COVID-19. The clinical, laboratory, and imaging 
features were collected and analyzed during admission. The Multi-lobular 
infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, 
hyper-Tension and Age (MuLBSTA) Score and Confusion, Urea, Respiratory rate, 
Blood pressure, Age 65 (CURB65) score were used to assess the death and 
intensive care unit (ICU) risks in all patients. Results: Among of all 117 
hospitalized patients, 21 (17.9%) patients were admitted to the ICU care, and 5 
(4.3%) patients were died. The median hospital stay was 12 (10-15) days. There 
were 18 patients with MuLBSTA score ≥ 12 points and were all of severe type. In 
severe type, ICU care and death patients, the proportion with MuLBSTA ≥ 12 
points were greater than that of CURB65 score ≥ 3 points (severe type patients, 
50 vs. 27.8%; ICU care, 61.9 vs. 19.0%; death, 100 vs. 40%). For the MuLBSTA 
score, the ROC curve showed good efficiency of diagnosis death (area under the 
curve [AUC], 0.956; cutoff value, 12; specificity, 89.5%; sensitivity, 100%) and 
ICU care (AUC, 0.875; cutoff value, 11; specificity, 91.7%; sensitivity, 71.4%). 
The K-M survival analysis showed that patients with MuLBSTA score ≥ 12 had 
higher risk of ICU (log-rank, P = 0.001) and high risk of death (log-rank, P = 
0.000). Conclusions: The MuLBSTA score is valuable for risk stratification and 
could effectively screen high-risk patients at admission. The higher score at 
admission have higher risk of ICU care and death in patients infected with 
COVID.